[Cystic fibrosis].
Yoshimura
K
K
Department of Gene Therapy, Jikei University School of Medicine.
Tada
H
H
Anzai
C
C
D015056:1-Methyl-3-isobutylxanthine / Q000627:therapeutic use; D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000584:Amiloride / Q000627:therapeutic use; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000209:etiology / Q000628:therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D003937:Diagnosis, Differential; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D009154:Mutation; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011379:Prognosis
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C505032:CFTR protein, human; D004232:Diuretics; D010726:Phosphodiesterase Inhibitors; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D000584:Amiloride; D000255:Adenosine Triphosphate; D015056:1-Methyl-3-isobutylxanthine